Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer (Journal article)

Aravantinos, G./ Dimopoulos, M. A./ Kosmidis, P./ Bafaloukos, D./ Papadimitriou, C./ Kiamouris, C./ Pavlidis, N./ Sikiotis, K./ Papakostas, P./ Skarlos, D. V.


BACKGROUND: The prognosis of platinum resistant ovarian cancer is very poor and the treatment of choice has not been clearly defined. PATIENTS AND METHODS: We conducted a phase II study with the combination of ifosfamide i.v. at 2.25 g/m2 (days 1, 2) and etoposide per os at 100 mg daily (days 1-10) every four weeks. To be eligible for the study patients had to be resistant to platinum and paclitaxel pretreated. RESULTS: Forty-one patients entered the study. The median interval from the previous chemotherapy was 3.9 months. The median number of previous chemotherapeutic regimens was 2. Severe toxicities included neutropenia (41% of patients), leukopenia (29%) and thrombocytopenia (13%). Thirty-five patients are assessable for response. Nine patients responded (22% of the eligible, 26% of the assessable), four of them demonstrated complete response to chemotherapy (10% and 12%, respectively), while three patients demonstrated stabilization of their progressive disease. After a median follow-up of 18 months, time to progression is 3 months (range 0.9-14.4), duration of response is 9 months (2.5-11) and median survival is 13 months (2.5-37.4+). CONCLUSIONS: The combination of ifosfamide with oral etoposide appears to have significant but manageable toxicity and encouraging efficacy in platinum resistant ovarian cancer.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Administration, Oral,Adult,Aged,Antineoplastic Agents, Phytogenic/administration & dosage,Antineoplastic Combined Chemotherapy Protocols/administration &,dosage/*therapeutic use,Disease Progression,Drug Resistance, Neoplasm,Etoposide/administration & dosage,Female,Humans,Ifosfamide/administration & dosage,Infusions, Intravenous,Middle Aged,Ovarian Neoplasms/*drug therapy/pathology,Paclitaxel/pharmacology,Prognosis,Salvage Therapy,Survival Analysis
URI: http://olympias.lib.uoi.gr/jspui/handle/123456789/21038
ISSN: 0923-7534
Link: http://www.ncbi.nlm.nih.gov/pubmed/10907957
http://annonc.oxfordjournals.org/content/11/5/607.full.pdf
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Aravantinos-2000-Ifosfamide plus oral.pdf578.6 kBAdobe PDFView/Open    Request a copy



 Please use this identifier to cite or link to this item:
http://olympias.lib.uoi.gr/jspui/handle/123456789/21038
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.